What could go wrong when your feed is flooded with GLP-1 content? A lot.

In contrast, one research trial using GLP-1 drugs on obese research subjects did not show a benefit from GLP-1 in the ...

As GLP-1 drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy have spent the last couple of years skyrocketing in popularity—with no signs of slowing down—it was perhaps only a matter ...

Glucagon-like peptide-1 receptor agonists (GLP-1s) have become well known for their significant role as an aid in weight loss ...

Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed ...

While blockbuster drug innovations have changed health outcomes for decades, we’re now seeing signs that GLP-1 medications like Ozempic and Wegovy may be changing something broader: the consumer ...

New research suggests GLP-1 drugs could reduce cancer risk. A doctor breaks down how that could change public health in the future.